Home Procurement NewsEli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

June 20, 2023•

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

Was this article helpful?

YesNo

Last modified: June 20, 2023

Previous: Carlos Ghosn sues Nissan for $1 billion in Lebanon, legal document shows

Next: Africa: Afreximbank Invests U.S.$6 Billion to Strengthen Africa’s Food Security

Leave a Reply Cancel reply

The articles and content featured on this platform are sourced from various contributors and do not necessarily reflect the views or positions of Accountability Lab Nigeria. We do not author or edit the published materials. If you have concerns about any content or would like to request its removal, please contact us at @Accountability Lab Nigeria.

Recent Posts

Recent Comments

No comments to show.

Are you ready to join the Community?

Join the Conversation!

Community of Practice Portal aims to bring together key stakeholders in the procurement landscape in Nigeria to leverage on each others skillset in relation to understanding Procurement data in a bid to use these data to create stories and to generate action from the government.

Community of practice platform is an initiative under Anti-Corruption Innovation Project, a UNDP funded Project in collaboration with Accountability lab Nigeria, and Open Contracting Partnerships

Accountability Lab Nigeria

Copyright © 2021 - Accountability Lab Nigeria

↑

Close